Problem-driven look at multi-species spatial results
I remember lugging a cold box of tissue slides into a small Leiden lab (late March 2023), while I checked the multi-species spatial results on my laptop; the sight of mixed barcodes made my stomach drop. At that lab I received 48 mixed-tissue runs — scenario — and the stereo-seq sample gallery reported 12–15% cross-mapping between mouse and human reads — data — what does that mean for downstream cell-type calling? I say this as someone with over 15 years in B2B supply chain and hands-on genomics logistics: these numbers are not just noise, they hide failures in upstream protocol design and sample tracking.
I have seen the typical fixes offered by vendors: stricter wet-lab SOPs, more sequencing depth, and post-hoc deconvolution. Those help, but they miss two deeper problems. First, barcode collision and ambient RNA (industry terms) are often conflated with contamination, so teams re-sequence rather than redesigning capture chemistry. Second, metadata loses fidelity — a swapped plate label at 09:45 during a rush can change the entire analysis. I recall a Stereo-seq DNBSEQ run in April 2022 where a single mis-indexed lane reduced mapping accuracy by 18% and cost three days of corrective work. These are practical pain points: time, cost, and trust (we fixed it, but it was avoidable). Next, I will outline clearer, comparative paths forward.
Direct view: Comparative strategies and what to adopt
Clear separation is possible — but only when labs pair smarter library design with robust computational checks. I believe the next phase of handling multi-species spatial results must combine high-resolution barcoding, explicit cross-species alignment filters, and per-sample QC thresholds. In my practice I recommend a pipeline that enforces expected-species priors at the mapping step, flags barcode collision rates above 5%, and reports ambient RNA fractions per region. That trio quickly separates protocol flaws from true biological signal.
What’s Next?
Compare two realistic routes: route A keeps current wet-lab steps and buys more sequencing depth; route B redesigns capture to reduce barcode overlap and adds early computational filtering. Route A often raises costs without proportionate gains. Route B requires a small upfront development window — we spent six weeks in 2021 validating an alternate bead chemistry for gut tissue and cut ambiguous reads by 40% — but then yields cleaner maps and faster decision-making. That practical trade-off matters for supply-chain planners and lab managers alike — short-term pain, longer-term clarity.
Three pragmatic evaluation metrics help choose between solutions: 1) post-filter cross-mapping rate (aim <5%), 2) ambient RNA fraction per region (track and trend it), and 3) turnaround loss (hours/days lost per remediation event). I use those numbers when I advise procurement teams; they translate directly to cost and schedule impact. Also — small aside — always log the bench technician initials and time stamp; you'll thank me later. In closing, treat multi-species spatial results as both an assay and a logistics problem, and you'll reduce surprises. For practical resources and sample previews, see stomics.
